The Effects of Intra-articular and Peri-articular Platelet-rich Plasma (PRP) Injections ın Chronic Knee Osteoarthritis
RecruitingNot applicableNCT07339137
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The primary objective of this study is to evaluate and compare the effectiveness of ultrasound-guided combined intra-articular and peri-articular platelet-rich plasma (PRP) injections with intra-articular PRP injections alone in patients with chronic knee osteoarthritis (OA). The study specifically examines the effects of these treatment approaches on pain, physical function, activities of daily living, and structural parameters, including medial collateral ligament (MCL) thickness and distal femoral cartilage thickness. Osteoarthritis is a degenerative joint disease characterized by progressive cartilage erosion, osteophyte formation, and subchondral sclerosis, leading to pain, stiffness, and functional disability. It is the most common form of arthritis and a leading cause of disability worldwide, affecting approximately 300 million individuals. Although the knee is the most frequently involved joint, OA is now recognized as a whole-joint disease, involving not only cartilage degeneration but also pathological changes in subchondral bone, synovium, and surrounding extra-articular structures. Platelet-rich plasma is an autologous concentration of platelets suspended in a small volume of plasma and contains a variety of bioactive growth factors, such as transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF). These factors play a crucial role in promoting cell proliferation, angiogenesis, and tissue repair. In knee OA, PRP has been shown to reduce matrix metalloproteinase (MMP) activity, particularly MMP-13, enhance endogenous hyaluronic acid production, and support chondrogenesis. Although intra-articular PRP injections are widely accepted as a safe and effective treatment and have demonstrated superiority over placebo and hyaluronic acid in long-term follow-up studies, most existing research has focused exclusively on intra-articular applications. Knee OA is a multifactorial condition frequently…
Study details
- Official title
- The Effects of Platelet-rich Plasma (PRP) Injections Administered Into Intra-articular and Periarticular Regions Under Ultrasound Guidance in Chronic Knee Osteoarthritis on Pain, Function, Activities of Daily Living, Medial Collateral Ligament (MCL) and Distal Femoral Cartilage Thickness
- Conditions
- Platelet Rich Plasma Injection
- Ultrasonography
- Gonarthrosis
- Interventions
- Behavioral: Conservative Therapy
- Procedure: Intra-Articular PRP
- Procedure: Peri-Articular PRP
- Sponsor
- Ankara City Hospital Bilkent
- Start date
- 2025-08-01
- Primary completion
- 2026-02-01
- Sex
- All
- Age range
- from 40 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- Turkey (Türkiye)
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria * Age between 40 and 65 years. * Patients with significant medial knee pain who have not responded to conservative treatment for at least 3 months. * Patients diagnosed with knee osteoarthritis according to the American College of Rheumatology (ACR) criteria and with Kellgren-Lawrence grade 2 or 3 radiographic osteoarthritis. * Intact cognitive function. * Willingness to participate in the study and provide signed informed consent. * Visual Analog Scale (VAS) score of 4 or higher. Exclusion Criteria * History of previous knee trauma or surgery. * Physical therapy, intra-articular steroid, or hyaluronic acid injections in the knee within the last 3 months. * Active oncological diseases. * Local infection, sepsis, wounds, or scars in the injection area. * Systemic infections, hepatitis, or immunosuppression. * Bleeding diathesis or irregular International Normalized Ratio (INR) due to oral warfarin use. * Inflammatory arthropathies. * Uncontrolled hypertension, uncontrolled diabetes mellitus, decompensated heart failure, coronary artery disease, or asthma. * Suspected or confirmed pregnancy. * Use of corticosteroids or opioids. * Anemia. * Body mass index (BMI) greater than 35. * Allergy to citrate. * Use of nonsteroidal anti-inflammatory drugs (NSAIDs) within the last week that may affect platelet function analyzer-100 (PFA-100) activity. * Physical examination findings suggestive of patellar retinaculum, meniscus, or cruciate ligament injury. * General health impairment or lack of cooperation. * Refusal to participate in the study.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07339137